Promsuk Jutabha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Promsuk Jutabha has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Hitoshi Endou
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, 181-8611, Japan
2 shared publications- Naohiko Anzai
Department of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan
2 shared publications - Ade Danova
Organic Chemistry Division, Department of Chemistry, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Jl. Ganesha 10, Bandung, West Java, 40132, Indonesia
1 shared publication - Amit Kumar
Department of Pharmaceutical Sciences School of Pharmacy University of Colorado Denver Anschutz Medical Campus 80045 Aurora CO USA
1 shared publication - Anaheed L Little
Department of Pharmaceutical Sciences School of Pharmacy University of Colorado Denver Anschutz Medical Campus 80045 Aurora CO USA
1 shared publication - Atsuo Taniguchi
Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1377-1392
Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies
Purpose: There were two main purposes for this study. One, to report two benzbromarone analogs and test their in vitro activity in the URAT1 inhibition assay; and two, to probe the structure–activity relationship (SAR) of various benzbromarone analogs regarding other drug transporters that may play a role in the uric acid uptake/elimination interplay. Methods: In brief, chemical synthesis of two benzbromarone analogs was prepared using methods analogous to those reported. Furthermore, drug transporter protein inhibition was investigated in vitro using oocytes expressing hURAT1, hURATv1 (GLUT9), hOAT1, hOAT3, hOAT10, hNPT4, OATP1B1, OATP1B3 and OATP2B1 prepared and utilized to conduct inhibition studies. In addition, one novel benzbromarone analog was studied via in vivo rat pharmacokinetic experiments to determine apparent oral bioavailability. Results: Two analogs, 6-fluoro-benzbromarone ( 5) and 5,6-difluoro-benzbromarone ( 9), were synthetically prepared and 5 had a hURAT1 IC50 inhibition of 18 ± 4 nM, while analog ( 9) had an IC50 of 245 ± 64 nM. Analog ( 5) had good oral bioavailability (Fa) > 0.6 in rat. Eadie-Hofstee plot and double-reciprocal plot of the Michaelis–Menten equation are summarized for benzbromarone ( 2) and its major Phase I metabolite 6-hydroxy-benzbromarone ( 3). Conclusion: These results illustrate that the Km for [14C]UA uptake was not altered in the presence of 2 or 3, but rather the Vmax was reduced in the presence of inhibitors when added to the uptake solutions. As a result, these data support the notion that 2 and 3 inhibit [14C]UA uptake by non-competitive inhibition and not at the URAT1 binding site.
- 1 February 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1377-1392
Open AccessBenzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies
Purpose: There were two main purposes for this study. One, to report two benzbromarone analogs and test their in vitro activity in the URAT1 inhibition assay; and two, to probe the structure–activity relationship (SAR) of various benzbromarone analogs regarding other drug transporters that may play a role in the uric acid uptake/elimination interplay. Methods: In brief, chemical synthesis of two benzbromarone analogs was prepared using methods analogous to those reported. Furthermore, drug transporter protein inhibition was investigated in vitro using oocytes expressing hURAT1, hURATv1 (GLUT9), hOAT1, hOAT3, hOAT10, hNPT4, OATP1B1, OATP1B3 and OATP2B1 prepared and utilized to conduct inhibition studies. In addition, one novel benzbromarone analog was studied via in vivo rat pharmacokinetic experiments to determine apparent oral bioavailability. Results: Two analogs, 6-fluoro-benzbromarone ( 5) and 5,6-difluoro-benzbromarone ( 9), were synthetically prepared and 5 had a hURAT1 IC50 inhibition of 18 ± 4 nM, while analog ( 9) had an IC50 of 245 ± 64 nM. Analog ( 5) had good oral bioavailability (Fa) > 0.6 in rat. Eadie-Hofstee plot and double-reciprocal plot of the Michaelis–Menten equation are summarized for benzbromarone ( 2) and its major Phase I metabolite 6-hydroxy-benzbromarone ( 3). Conclusion: These results illustrate that the Km for [14C]UA uptake was not altered in the presence of 2 or 3, but rather the Vmax was reduced in the presence of inhibitors when added to the uptake solutions. As a result, these data support the notion that 2 and 3 inhibit [14C]UA uptake by non-competitive inhibition and not at the URAT1 binding site.
- Open Access
- 1 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 42
Potential Interaction of Pinocembrin with Drug Transporters and Hepatic Drug-Metabolizing Enzymes
Background/Objectives: Pinocembrin is a promising drug candidate for treating ischemic stroke. The interaction of pinocembrin with drug transporters and drug-metabolizing enzymes is not fully revealed. The present study aims to evaluate the interaction potential of pinocembrin with cytochrome P450 (CYP450: CYP2B6, CYP2C9, and CYP2C19) and drug transporters including organic anion transporters (OAT1 and OAT3), organic cation transporters (OCT1 and OCT2), multidrug and toxin extrusion (MATE1 and MATE2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). Methods: The interactions of pinocembrin on drug transporters were determined in the Madin–Darby canine kidney (MDCK) cells overexpressing human (h)OAT1 or hOAT3 and in the Chinese hamster ovary (CHO-K1) cells overexpressing hOCT1, hOCT2, hMATE1, or hMATE2. The interactions of pinocembrin with BCRP and P-glycoprotein were determined in Caco-2 cells. The CYP450 enzyme inhibitory activity was assessed by a cell-free CYP450 screening assay. Results: Pinocembrin effectively inhibited the function of OAT1 and OAT3 with a half-inhibitory concentration (IC50) and inhibitory constant (Ki) of ∼2 μM. In addition, it attenuated the toxicity of tenofovir, a substrate of hOAT1, in cells overexpressing hOAT1. Based on the kinetic study and molecular docking, pinocembrin inhibited OAT1 and OAT3 via a competitive inhibition. In contrast to hOAT1 and hOAT3, pinocembrin did not significantly inhibit the function of OCT1, OCT2, MATE1, MATE2, BCRP, and P-glycoprotein. In addition, pinocembrin potently inhibited the activity of CYP2C19, whereas it exhibited low inhibitory potency on CYP2B6 and CYP2C9. Conclusions: The present study reveals the potential drug interaction of pinocembrin on OAT1, OAT3, and CYP2C19. Co-administration with pinocembrin might affect OAT1-, OAT3-, and CYP2C19-mediated drug pharmacokinetic profiles.
- 1 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 42
Open AccessPotential Interaction of Pinocembrin with Drug Transporters and Hepatic Drug-Metabolizing Enzymes
Background/Objectives: Pinocembrin is a promising drug candidate for treating ischemic stroke. The interaction of pinocembrin with drug transporters and drug-metabolizing enzymes is not fully revealed. The present study aims to evaluate the interaction potential of pinocembrin with cytochrome P450 (CYP450: CYP2B6, CYP2C9, and CYP2C19) and drug transporters including organic anion transporters (OAT1 and OAT3), organic cation transporters (OCT1 and OCT2), multidrug and toxin extrusion (MATE1 and MATE2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). Methods: The interactions of pinocembrin on drug transporters were determined in the Madin–Darby canine kidney (MDCK) cells overexpressing human (h)OAT1 or hOAT3 and in the Chinese hamster ovary (CHO-K1) cells overexpressing hOCT1, hOCT2, hMATE1, or hMATE2. The interactions of pinocembrin with BCRP and P-glycoprotein were determined in Caco-2 cells. The CYP450 enzyme inhibitory activity was assessed by a cell-free CYP450 screening assay. Results: Pinocembrin effectively inhibited the function of OAT1 and OAT3 with a half-inhibitory concentration (IC50) and inhibitory constant (Ki) of ∼2 μM. In addition, it attenuated the toxicity of tenofovir, a substrate of hOAT1, in cells overexpressing hOAT1. Based on the kinetic study and molecular docking, pinocembrin inhibited OAT1 and OAT3 via a competitive inhibition. In contrast to hOAT1 and hOAT3, pinocembrin did not significantly inhibit the function of OCT1, OCT2, MATE1, MATE2, BCRP, and P-glycoprotein. In addition, pinocembrin potently inhibited the activity of CYP2C19, whereas it exhibited low inhibitory potency on CYP2B6 and CYP2C9. Conclusions: The present study reveals the potential drug interaction of pinocembrin on OAT1, OAT3, and CYP2C19. Co-administration with pinocembrin might affect OAT1-, OAT3-, and CYP2C19-mediated drug pharmacokinetic profiles.
- Open Access
- 10 July 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 165, 115098
Discovery of a chalcone derivative as an anti-fibrotic agent targeting transforming growth factor-β1 signaling: Potential therapy of renal fibrosis
- 10 July 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 165, 115098
Open AccessDiscovery of a chalcone derivative as an anti-fibrotic agent targeting transforming growth factor-β1 signaling: Potential therapy of renal fibrosis
- Open Access
- 5 May 2015
- Published by European Society of Medicine in Medical Research Archives
- No. 3
EZH2 Inhibitor GSK126: Metabolism, drug transporter and rat pharmacokinetic studies
Histone lysine methyl transferase 2 (EZH2) inhibitor GSK126 and a novel deuterated internal standard GSK126-d7 were chemically prepared. We performed in vitro experiments using the prepared GSK126 to: i) confirm in vitro EZH2 inhibitory activity; ii) conduct Sprague-Dawley (SD) rat liver microsomal incubations and identified Phase I metabolites; iii) determine whether or not GSK126 was an Organic Anion Transporter (OAT) substrate; and, iv) determine oral bioavailability by conducting oral and orbital sinus dosing (OSD) experiments and determining blood concentration versus time profiles. GSK126 was shown to decrease the expression of H3K27Me3 protein in medulloblastoma D283 cells and was able to decrease cell viability in KO99L cells, a novel T cell lymphoma cell line. Three in vitro hepatic Phase I mono-oxidative metabolites (L-M1, L-M2 and L-M3) were observed and also detected in rat liver and urine samples from the in vivo studies. GSK126 was found to be an OAT1 and OAT2 substrate, but not an OAT3 or OAT4 substrate. Our Pharmacokinetic (PK) results indicate: 1) GSK126 has very poor oral bioavailability (< 2%); 2) co-administration of probenecid, a prototypical OAT inhibitor, did not significantly alter observed PK; and 3) tissue distribution studies demonstrate that GSK126 predominately distributes to the liver and kidneys after an OSD.
- 5 May 2015
- Published by European Society of Medicine in Medical Research Archives
- No. 3
Open AccessEZH2 Inhibitor GSK126: Metabolism, drug transporter and rat pharmacokinetic studies
Histone lysine methyl transferase 2 (EZH2) inhibitor GSK126 and a novel deuterated internal standard GSK126-d7 were chemically prepared. We performed in vitro experiments using the prepared GSK126 to: i) confirm in vitro EZH2 inhibitory activity; ii) conduct Sprague-Dawley (SD) rat liver microsomal incubations and identified Phase I metabolites; iii) determine whether or not GSK126 was an Organic Anion Transporter (OAT) substrate; and, iv) determine oral bioavailability by conducting oral and orbital sinus dosing (OSD) experiments and determining blood concentration versus time profiles. GSK126 was shown to decrease the expression of H3K27Me3 protein in medulloblastoma D283 cells and was able to decrease cell viability in KO99L cells, a novel T cell lymphoma cell line. Three in vitro hepatic Phase I mono-oxidative metabolites (L-M1, L-M2 and L-M3) were observed and also detected in rat liver and urine samples from the in vivo studies. GSK126 was found to be an OAT1 and OAT2 substrate, but not an OAT3 or OAT4 substrate. Our Pharmacokinetic (PK) results indicate: 1) GSK126 has very poor oral bioavailability (< 2%); 2) co-administration of probenecid, a prototypical OAT inhibitor, did not significantly alter observed PK; and 3) tissue distribution studies demonstrate that GSK126 predominately distributes to the liver and kidneys after an OSD.
- 1 December 2011
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 30 (12) , 1302-1311
Apical Voltage-Driven Urate Efflux Transporter NPT4 in Renal Proximal Tubule
Uric acid (urate) is the end product of purine metabolism in humans. Human kidneys reabsorb a large proportion of filtered urate. This extensive renal reabsorption, together with the fact that humans do not possess uricase that catalyzes the biotransformation of urate into allantoin, results in a higher plasma urate concentration in humans compared to other mammals. A major determinant of plasma urate concentration is renal excretion as a function of the balance between reabsorption and secretion. We previously identified that renal urate absorption in proximal tubular epithelial cells occurs mainly via apical urate/anion exchanger, URAT1/SLC22A12, and by facilitated diffusion along the trans-membrane potential gradient by the basolateral voltage-driven urate efflux transporter, URATv1/SLC2A9/GLUT9. In contrast, the molecular mechanism by which renal urate secretion occurs remains elusive. Recently, we reported a newly characterized human voltage-driven drug efflux transporter, hNPT4/SLC17A3, which functions as a urate exit pathway located at the apical side of renal proximal tubules. This transporter protein has been hypothesized to play an important role with regard to net urate efflux. An in vivo role of hNPT4 is supported by the fact that missense mutations in SLC17A3 present in hyperuricemia patients with urate underexcretion abolished urate efflux capacity in vitro. Herein, we report data demonstrating that loop diuretics and thiazide diuretics substantially interact with hNPT4. These data provide molecular evidence for loop and thiazide-diuretics-induced hyperuricemia. Thus, we propose that hNPT4 is an important transepithelial proximal tubular transporter that transports diuretic drugs and operates functionally with basolateral organic anion transporters 1/3 (OAT1/OAT3).
- 1 December 2011
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 30 (12) , 1302-1311
Apical Voltage-Driven Urate Efflux Transporter NPT4 in Renal Proximal Tubule
Uric acid (urate) is the end product of purine metabolism in humans. Human kidneys reabsorb a large proportion of filtered urate. This extensive renal reabsorption, together with the fact that humans do not possess uricase that catalyzes the biotransformation of urate into allantoin, results in a higher plasma urate concentration in humans compared to other mammals. A major determinant of plasma urate concentration is renal excretion as a function of the balance between reabsorption and secretion. We previously identified that renal urate absorption in proximal tubular epithelial cells occurs mainly via apical urate/anion exchanger, URAT1/SLC22A12, and by facilitated diffusion along the trans-membrane potential gradient by the basolateral voltage-driven urate efflux transporter, URATv1/SLC2A9/GLUT9. In contrast, the molecular mechanism by which renal urate secretion occurs remains elusive. Recently, we reported a newly characterized human voltage-driven drug efflux transporter, hNPT4/SLC17A3, which functions as a urate exit pathway located at the apical side of renal proximal tubules. This transporter protein has been hypothesized to play an important role with regard to net urate efflux. An in vivo role of hNPT4 is supported by the fact that missense mutations in SLC17A3 present in hyperuricemia patients with urate underexcretion abolished urate efflux capacity in vitro. Herein, we report data demonstrating that loop diuretics and thiazide diuretics substantially interact with hNPT4. These data provide molecular evidence for loop and thiazide-diuretics-induced hyperuricemia. Thus, we propose that hNPT4 is an important transepithelial proximal tubular transporter that transports diuretic drugs and operates functionally with basolateral organic anion transporters 1/3 (OAT1/OAT3).
- Open Access
- 1 April 2010
- Published by Wiley in The FASEB Journal
- Vol. 24 (S1) , 606.34
Mutations in renal drug efflux transporter hOATv1 cause hyperuricemia
Hyperuricemia, traditionally linked to gout, has recently been implicated in cardiovascular diseases and hypertension. One of the major determinants of plasma urate concentration is renal excretion that is dependent on the balance between reabsorption and secretion. Previously we identified that renal urate absorption is mainly performed by apical urate/anion exchanger, URAT1/ SLC22A12 , and basolateral voltage‐driven urate efflux transporter, URATv1/ SLC2A9 in tandem in proximal tubular cells. In contrast, the molecular mechanism of renal urate secretion remains elusive. Here, we report that newly characterized human renal voltage‐driven drug efflux transporter, hOATv1 also functions as a long‐hypothesized urate exit pathway at the apical side of renal proximal tubules that determines the direction of net urate flux. Loop diuretics such as furosemide and bumetanide substantially interacted with hOATv1, providing the first molecular evidence for loop diuretics‐induced hyperuricemia. The in vivo role of hOATv1 is supported by the fact that missense mutations in this transporter found in hyperuricemia patients with urate underexcretion abolished urate efflux capacity in vitro . Our results demonstrate that hOATv1 is component of renal urate secretory pathway involved in the formation of both in primary and secondary hyperuricemia.
- 1 April 2010
- Published by Wiley in The FASEB Journal
- Vol. 24 (S1) , 606.34
Open AccessMutations in renal drug efflux transporter hOATv1 cause hyperuricemia
Hyperuricemia, traditionally linked to gout, has recently been implicated in cardiovascular diseases and hypertension. One of the major determinants of plasma urate concentration is renal excretion that is dependent on the balance between reabsorption and secretion. Previously we identified that renal urate absorption is mainly performed by apical urate/anion exchanger, URAT1/ SLC22A12 , and basolateral voltage‐driven urate efflux transporter, URATv1/ SLC2A9 in tandem in proximal tubular cells. In contrast, the molecular mechanism of renal urate secretion remains elusive. Here, we report that newly characterized human renal voltage‐driven drug efflux transporter, hOATv1 also functions as a long‐hypothesized urate exit pathway at the apical side of renal proximal tubules that determines the direction of net urate flux. Loop diuretics such as furosemide and bumetanide substantially interacted with hOATv1, providing the first molecular evidence for loop diuretics‐induced hyperuricemia. The in vivo role of hOATv1 is supported by the fact that missense mutations in this transporter found in hyperuricemia patients with urate underexcretion abolished urate efflux capacity in vitro . Our results demonstrate that hOATv1 is component of renal urate secretory pathway involved in the formation of both in primary and secondary hyperuricemia.